Can a Low-Dose drug delay menopause? new trial aims to find out
NCT ID NCT05836025
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests whether low-dose rapamycin can slow ovarian aging in 50 women aged 35-45 who are in early perimenopause. Participants take 5mg of rapamycin or a placebo weekly for 12 weeks. Researchers will measure hormone levels and ovarian reserve to see if the drug delays age-related decline.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Rapamycin (low dose, 5mg/week for 12 weeks)
- What this could lead to
- If it works, this could point toward a way to slow ovarian aging and extend fertility in perimenopausal women.
- What could go wrong
- This is a small, early-phase pilot study with only 50 participants. Results may not apply to all women, and the effect on fertility is not directly tested.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIMENOPAUSAL are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Columbia University Irving Medical Center / NewYork-Presbyterian Hospital
New York, New York, 10032, United States